In a 20‑year‑old male with stable obsessive‑compulsive disorder on fluvoxamine 150 mg daily and aripiprazole (Abilify) 10 mg daily, how should excessive daytime sleepiness and difficulty getting out of bed be managed?

Management of Excessive Daytime Sleepiness in OCD Patient on Fluvoxamine and Aripiprazole

The most appropriate first step is to reduce or discontinue aripiprazole, as it is the most likely culprit for medication-induced sedation in this patient with stable OCD. 1

Rationale and Clinical Approach

Identifying the Cause

Your patient's excessive sleepiness and difficulty waking is most likely drug-induced hypersomnia from aripiprazole. The evidence-based guidelines are clear: in patients with drug- or medication-induced sedation, the treatment is to reduce or remove the offending drug or substance 1.

Aripiprazole (Abilify) is well-documented to cause drowsiness and sedation 2. The FDA label explicitly warns that "ABILIFY may make you drowsy" and advises patients not to drive or operate machinery until they know how it affects them 2. Additionally, aripiprazole can cause orthostatic hypotension and falls due to sleepiness, dizziness, and slowed motor skills 2.

In contrast, fluvoxamine—while listed among medications that can affect sleep 3—is more commonly associated with insomnia rather than hypersomnia. SSRIs like fluvoxamine typically cause sleep disruption, not excessive sedation 3, 1.

Recommended Management Algorithm

Step 1: Taper and discontinue aripiprazole

• Since the patient's OCD is stable, aripiprazole augmentation may no longer be necessary
• Aripiprazole was likely added for treatment-resistant OCD 4, but with current stability, the risk-benefit ratio now favors discontinuation
• Taper gradually to avoid withdrawal effects (though aripiprazole has relatively low withdrawal risk)

Step 2: Monitor OCD symptoms closely

• Assess for any return of obsessive-compulsive symptoms over 4-6 weeks
• Use standardized measures if available (Yale-Brown Obsessive Compulsive Scale)
• If OCD remains stable, continue fluvoxamine monotherapy at 150 mg

Step 3: If OCD symptoms worsen after aripiprazole discontinuation

• Consider alternative augmentation strategies that don't cause sedation
• Optimize fluvoxamine dosing (can go up to 300 mg/day, or even higher in treatment-resistant cases 5)
• Consider switching to a different augmentation agent with less sedating properties

Step 4: If sleepiness persists despite aripiprazole discontinuation

• Re-evaluate for primary sleep disorders (sleep apnea, narcolepsy, idiopathic hypersomnia)
• Assess for other contributing factors: depression, hypothyroidism, other medical conditions 1
• Consider sleep study if indicated

Important Clinical Considerations

Why Not Adjust Timing or Dose First?

While moving aripiprazole to bedtime might seem logical, the guidelines emphasize removal rather than adjustment when medication-induced sedation impairs quality of life 1. The patient is already experiencing functional impairment (difficulty getting up), which affects daily functioning and quality of life—key outcomes that should guide treatment decisions.

The Role of Fluvoxamine

Fluvoxamine at 150 mg is a moderate dose (typical range 100-300 mg/day) 6, 7. It has demonstrated efficacy for OCD as monotherapy 6, 7, 5, and there's evidence that OCD patients can maintain remission without augmentation agents. One study showed that concentrated exposure therapy alone led to significant OCD improvement, suggesting that not all patients require ongoing augmentation 8.

Safety Monitoring

When discontinuing aripiprazole:

• Monitor for metabolic changes (aripiprazole affects glucose and lipids) 2
• Watch for movement disorders (though these are more concerning with long-term use) 2
• Assess mood stability, as aripiprazole has mood-stabilizing properties 2

Common Pitfall to Avoid

Do not assume the patient needs both medications indefinitely. Aripiprazole augmentation is typically used for treatment-resistant OCD 4, but once stability is achieved, the need for continued augmentation should be reassessed. The principle of using "the smallest dose and shortest duration producing satisfactory clinical response" applies here 2.

This therapy should be instituted under guidance of both a sleep specialist (if needed) and the patient's primary care physician or psychiatrist who knows the patient's medical problems and medications 1.